Daniel O Claassen
Overview
Explore the profile of Daniel O Claassen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
170
Citations
2085
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stark A, Han C, Eisma J, Song A, Garza M, Mann L, et al.
Clin EEG Neurosci
. 2025 Feb;
:15500594251320294.
PMID: 39962813
Magnetic resonance imaging (MRI) sequences commonly used in simultaneous electroencephalogram (EEG)-MRI studies include blood oxygenation level-dependent (BOLD) and anatomical T-weighted MRI. Safety and electrode heating profiles for these sequences have...
2.
Watson K, Ciriegio A, Pfalzer A, Snow A, Diehl S, McDonell K, et al.
J Neuropsychiatry Clin Neurosci
. 2025 Jan;
:appineuropsych20240104.
PMID: 39885721
Objective: Using a multi-informant approach, the authors assessed the psychiatric symptoms of adolescents and young adults with or without the huntingtin gene expansion and examined the association of psychiatric symptoms...
3.
Considine C, Eddy C, Frank S, Kostyk S, Oosterloo M, Killoran A, et al.
Neurol Clin Pract
. 2025 Jan;
15(2):e200427.
PMID: 39830677
Background: Huntington disease (HD) is a genetic neurodegenerative disorder. Given the focus on motor manifestations, nonmotor symptoms are frequently underappreciated in clinical evaluations, despite frequently contributing to primary functional impairment....
4.
Trujillo P, ORourke K, Roman O, Song A, Hett K, Cooper A, et al.
Mov Disord
. 2025 Jan;
PMID: 39825743
Background: Central synucleinopathies, including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), involve alpha-synuclein accumulation and dopaminergic cell loss in the substantia nigra (SN) and...
5.
Furr Stimming E, Claassen D, Sen G, Klepitskaya O, Serbin M, Kim H, et al.
Neurol Ther
. 2025 Jan;
PMID: 39815077
Introduction: Chorea is the primary manifestation of Huntington's disease. Different clinicians pursue varied approaches to chorea management, and real-world evidence describing them is needed. The objective of this study was...
6.
Gibson J, Hay K, Claassen D, McDonell K, Brown A, Wynn A, et al.
J Neuropsychiatry Clin Neurosci
. 2024 Nov;
appineuropsych20230225.
PMID: 39558706
Objective: Apathy is common in Huntington's disease (HD) and difficult to treat. Multiple recent calls have been made to increase understanding of apathy across the spectrum of HD severity. Functional...
7.
Leguizamon M, McKnight C, Ponzo T, Elenberger J, Eisma J, Song A, et al.
NPJ Parkinsons Dis
. 2024 Sep;
10(1):177.
PMID: 39304673
Intravenous arachnoid granulations (AGs) are protrusions of the arachnoid membrane into the venous lumen and function as contributors to the cerebrospinal fluid (CSF) flow circuit. Patients with Parkinson disease (PD)...
8.
Frank S, Anderson K, Fernandez H, Hauser R, Claassen D, Stamler D, et al.
Neurol Ther
. 2024 Sep;
13(6):1747-1749.
PMID: 39266813
No abstract available.
9.
Guzauskas G, Tabrizi S, Long J, Arnesen A, Hamilton J, Claassen D, et al.
Neurol Clin Pract
. 2024 Aug;
14(5):e200340.
PMID: 39161748
Background And Objectives: Disease-modifying treatments (DMTs) such as gene therapy are currently under investigation as a potential treatment for Huntington disease (HD). Our objective was to estimate the long-term natural...
10.
Snow A, Ciriegio A, Watson K, Baumann M, Pfalzer A, Diehl S, et al.
J Huntingtons Dis
. 2024 Aug;
13(3):339-347.
PMID: 39150832
Background: Huntington's disease (HD) presents patients and individuals at risk for HD with significant levels of stress. However, relatively little research has examined how individuals cope with stress related to...